·þÎñÈÈÏß
2121·Ç·²ÌṩÖÜÈ«JAKÒÖÖÆ¼ÁÆÀ¼Ûϵͳ
Ðû²¼Ê±¼ä£º£º
2021-01-20
JAKÒÖÖÆ¼ÁÖ÷ÒªÓÃÓÚÖÎÁÆÑªÒºÏµÍ³¼²²¡¡¢Ö×Áö¡¢Àà·çʪÐÔÊàŦÑ×¼°ÒøÐ¼²¡µÈ¼²²¡£¬·ÅÑÛÈ«ÇòºÍº£ÄÚ£¬JAKÒÖÖÆ¼ÁÓÈÆäÊǵڶþ´úJAKÒÖÖÆ¼ÁµÄÑз¢´¦ÓÚ»ðÈȽ׶Σ¬ÆäÖÐ×îÒªº¦µÄ»·½ÚÊÇÔõÑù¾«×¼¡¢¸ßЧɸѡ³ö¸ßÑ¡ÔñÐÔµÄJAKÒÖÖÆ¼Á¡£Îª´Ë£¬2121·Ç·²¿ª·¢ÁËJAKÒÖÖÆ¼ÁµÄÖÜÈ«ÆÀ¼Ûϵͳ£¬°üÀ¨Ba/F3¼¤Ã¸°Ðµã¹¤³Ìϸ°ûÖê¡¢»ùÓÚELISA, Phosho-Flow£¬AlphaELISA¼ì²âµÄȫѪ/ϸ°ûϵ/Tϸ°û·Ö»¯µÈÆÀ¼Ûƽ̨£¬×ÊÖú¿Í»§Ìá¸ßÐÂÒ©Ñз¢×¼È·ÂʺÍЧÂÊ¡£
¹ØÓÚJAK¼¤Ã¸¼°JAK-STATÐźÅͨ·
JAK¼Ò×å
Janus Kinase(JAK)ÊÇÒ»Àà°ûÄÚ·ÇÊÜÌåÀÒ°±Ëἤø£¬JAK¼Ò×åÓÐ4¸ö³ÉÔ±£º£ºJAK1¡¢JAK2¡¢JAK3ºÍTYK2¡£JAK1¡¢JAK2ºÍTYK2ÆÕ±é±£´æÓÚÈËÌ壬¶øJAK3Ö÷Òª±£´æÓÚ¹ÇËèϸ°û¡¢ÐØÏÙϸ°ûºÍÃâÒßϸ°ûÖС£
µ±´Ì¼¤Òò×ÓÓëÏìÓ¦ÊÜÌåÁ¬Ïµºó£¬ÒýÆðÊÜÌ屬·¢¾Û»¯£¬Ê¹µÃÓëÊÜÌåżÁªµÄJAK¼¤Ã¸Ï໥¿¿½ü£¬´ß»¯ÊÜÌåÉϵÄTyr²Ð»ù±¬·¢Á×Ëữ£¬½øÒ»²½ÕÐļÖÜΧSTATÂѰף¬¼Ì¶øJAK¼¤Ã¸´ß»¯Á¬ÏµÔÚÊÜÌåÉϵÄSTAT±¬·¢Á×Ëữ²¢¼¤»î£¬×îºóÒÔ¶þ¾ÛÌåµÄÐÎÊ½×ªÒÆÖÁϸ°ûºËÄÚ£¬µ÷¿ØÏìÓ¦µÄ°Ð»ùÒòת¼ºÍ±í´ï(ͼ1)¡£
ͼ1. JAK¼¤Ã¸¼ò½é
(ͼƬȪԴ£º£º×óͼȪԴÓڲο¼×ÊÁÏ[1])
JAK-STATÐźÅͨ·
JAK¼¤Ã¸ÓëÐźÅתµ¼¼°×ªÂ¼¼¤»îÂѰ×(Singal transducers and activators of transcription, STAT)Ö®¼äµÄÏ໥×÷ÓÃÔÚϸ°ûÒò×Ó¡¢¼¤Ëؼ°Ç÷»¯Òò×ÓµÈÊÜÌåÐźÅͨ·ÖÐʩչ×ÅÖ÷Òª×÷Óã¬Èç°×½éËØ¡¢×ÌÈÅËØºÍ¼¯Âä´Ì¼¤Òò×ӵȡ£Òò´Ë£¬JAK-STATÐźÅͨ·¹¦Ð§ÆÕ±é£¬¼ÓÈëϸ°ûµÄÔöÖ³¡¢·Ö»¯ÒÔ¼°ÃâÒßµ÷ÀíµÈÖî¶àÖ÷ÒªµÄÉúÎïѧÀú³Ì£¨Í¼2£©£¬µ«JAK¼¤Ã¸Ì«¹ý»î»¯»áµ¼ÖÂÑ×Ö¢µÈ¼²²¡µÄ±¬·¢¡£

ͼ2. JAK-STATͨ·¼ÓÈëµÄϸ°ûÖÖÖÖÉúÎïѧÀú³Ì(ͼƬȪԴ£º£º²Î¿¼×ÊÁÏ[2])
×÷ΪҩÎï°Ðµã¿ª·¢ÒÔÀ´£¬JAKÒѾ×ß¹ýÁ˽ü30ÄêµÄ·çÓêÀú³Ì£¬³ÉΪÑ×Ö¢¡¢×ÔÉíÃâÒß²¡¡¢°©Ö¢µÈÁìÓòµÄÈÈÃŰе㣬Èçͼ3Ëùʾ¡£JAKÒÖÖÆ¼Á³ýÁËÔÚÀà·çʪÊàŦÑ×ÖÐÁÆÐ§Í»³öÍ⣬ÉÐÓжàÖÖ˳Ӧ֢±»Åú»ò´¦ÓÚÁÙ´²Ñо¿½×¶Î£¬°üÀ¨£º£º¹ÇËèÔöÉúÐÔÖ×Áö¡¢ÒÆÖ²ÎËÞÖ÷²¡¡¢ÒøÐ¼²¡ÊàŦÑס¢Ñ×Ö¢ÐÔ³¦²¡¡¢ºì°ßÀÇ´¯ºÍǿֱ¼¹ÖùÑ׵ȡ£
ͼ3. JAK²î±ðÑÇÐÍÂþÑܼ°ÏìÓ¦ÒÖÖÆ¼Á
(ͼƬȪԴ£º£º²Î¿¼×ÊÁÏ[1])
2121·Ç·²Îª¿Í»§ÌṩÖÜÈ«JAKÒÖÖÆ¼ÁÆÀ¼Ûϵͳ
²¿·Öϸ°ûÑéÖ¤Êý¾Ý
PARTIAL DATA
1¡¢Ba/F3-TEL-JAK1ϸ°ûÔöֳʵÑéÊý¾Ý
2¡¢Ba/F3-EPOR-JAK2-V617Fϸ°ûÔöÖ³¼°ÌåÄÚҩЧʵÑéÊý¾Ý
3¡¢Ba/F3-FL-TYK2£¨È«³¤ÐòÁУ©ÊÔÑéÊý¾Ý±ÈÕÕ
×óͼ£º£ºBMS½ÒÏþÎÄÕÂÖÐʹÓÃHTRF ¼ì²âBMS-986165ºÍTYK2-JH2µÄÁ¬ÏµÄÜÁ¦;
ÓÒͼ£º£ºÊ¹ÓÃ2121·Ç·²¹¹½¨µÄBa/F3-FL-TYK2(JH1 JH2)ϸ°û¿ÉÒÔÖ±½Ó¼ì²âBMS-986165µÈ±ä¹¹¼Á¶Ôϸ°ûÔöÖ³µÄÒÖÖÆ»îÐÔ¡£
×ÊÁϲο¼£º£º
[1]SCHWARTZ D M, KANNO Y, VILLARINO A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases [J]. Nature Reviews Drug Discovery, 2017, 16(12): 843-62.
[2]¹ÙÍø¹ûÕæÐÅÏ¢

2121·Ç·²¹«ÖÚºÅ

Á¢ÒìÒ©ÎïÆÀ¼Û

ÖпÆÒ½ÂöС³ÌÐò
µç»°£º£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
ÍøÖ·£º£ºwww.precedo.cn
µØµã£º£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 2121·Ç·² °æÈ¨ËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺£ºÖÐÆó¶¯Á¦ ºÏ·Ê